Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00226473
Status:
UNKNOWN
Last Update Posted:
2006-06-21
First Post:
2005-09-25
Brief Title:
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
Sponsor:
Dermatologic Cooperative Oncology Group
Organization:
Dermatologic Cooperative Oncology Group
Study Overview
Official Title:
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy CVD-Protocol in the Second-Line Therapy of Distant Metastasized Malignant Melanoma
Status:
UNKNOWN
Status Verified Date:
2005-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this multicenter study is to examine whether the proposed randomized treatment regime results in a significantly longer survival time and higher quality of life than any additionally applied multiple chemotherapy according to the CVD- scheme So far neither established treatment regimes nor reliable data exist for the second-line chemotherapy of metastatic malignant melanoma Patients are therefore mostly treated with single or multiple chemotherapeutics orand immunomodulatory therapeutics These regimes however imply often not only a higher toxicity but show rarely a response rate higher than 10
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None